- Home
- MLCO vs BLTE Comparison
MLCO vs BLTE Comparison
Compare MLCO & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLCO
- BLTE
- Stock Information
- Founded
- MLCO 2004
- BLTE 2018
- Country
- MLCO Hong Kong
- BLTE United States
- Employees
- MLCO N/A
- BLTE N/A
- Industry
- MLCO Hotels/Resorts
- BLTE Biotechnology: Pharmaceutical Preparations
- Sector
- MLCO Consumer Discretionary
- BLTE Health Care
- Exchange
- MLCO Nasdaq
- BLTE Nasdaq
- Market Cap
- MLCO 2.5B
- BLTE 2.1B
- IPO Year
- MLCO 2006
- BLTE 2022
- Fundamental
- Price
- MLCO $5.45
- BLTE $65.39
- Analyst Decision
- MLCO Buy
- BLTE Strong Buy
- Analyst Count
- MLCO 6
- BLTE 4
- Target Price
- MLCO $7.70
- BLTE $96.33
- AVG Volume (30 Days)
- MLCO 3.7M
- BLTE 59.4K
- Earning Date
- MLCO 04-29-2025
- BLTE 03-17-2025
- Dividend Yield
- MLCO N/A
- BLTE N/A
- EPS Growth
- MLCO N/A
- BLTE N/A
- EPS
- MLCO 0.10
- BLTE N/A
- Revenue
- MLCO $4,638,213,000.00
- BLTE N/A
- Revenue This Year
- MLCO $6.59
- BLTE N/A
- Revenue Next Year
- MLCO $5.00
- BLTE N/A
- P/E Ratio
- MLCO $55.28
- BLTE N/A
- Revenue Growth
- MLCO 22.86
- BLTE N/A
- 52 Week Low
- MLCO $4.78
- BLTE $31.00
- 52 Week High
- MLCO $8.90
- BLTE $86.53
- Technical
- Relative Strength Index (RSI)
- MLCO 43.11
- BLTE 57.47
- Support Level
- MLCO $5.29
- BLTE $65.10
- Resistance Level
- MLCO $5.64
- BLTE $67.90
- Average True Range (ATR)
- MLCO 0.20
- BLTE 2.35
- MACD
- MLCO -0.01
- BLTE -0.08
- Stochastic Oscillator
- MLCO 24.62
- BLTE 51.50
About MLCO Melco Resorts & Entertainment Limited
Melco Resorts & Entertainment is one of only six licensed casino operators in Macao. It operates Altira, a complex focused on premium customers; City of Dreams, an integrated resort in Cotai serving both mass-market and premium patrons; and Mocha Clubs electronic gaming machines. The company also has a majority interest in Studio City, which opened in 2015. Outside Macao, Melco owns City of Dreams Manila in the Philippines and City of Dreams Mediterranean in Cyprus. The business mix in terms of adjusted EBITDA was about 84% from Macao with the rest largely from the Philippines as of 2019.
About BLTE Belite Bio Inc
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.